Non Hodgkin's Lymphoma Clinical Trial
Official title:
A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
The main treatments for non-Hodgkin's lymphoma are surgery, radiotherapy, chemotherapy, and bone marrow transplantation. Neutropenia is the most common and serious complication of most chemotherapy. This study is a multi-center, open-label, single-arm clinical study to evaluate the efficacy and safety of jinyouli in preventing neutropenia in patients with non Hodgkin's lymphoma after chemotherapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06014073 -
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
| Terminated |
NCT00909948 -
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
| Recruiting |
NCT05370547 -
Chidamide Bridging for CAR-T Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06285422 -
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
|
Phase 1 | |
| Withdrawn |
NCT01101581 -
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
|
Phase 1/Phase 2 | |
| Completed |
NCT00477945 -
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL
|
Phase 1 | |
| Terminated |
NCT00038818 -
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
|
N/A | |
| Withdrawn |
NCT01789723 -
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
|
Phase 1 | |
| Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 | |
| Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
| Terminated |
NCT00714259 -
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
|
Phase 2/Phase 3 | |
| Completed |
NCT01018758 -
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
|
Phase 2 | |
| Completed |
NCT00001830 -
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
|
Phase 1 | |
| Recruiting |
NCT01063439 -
BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)
|
Phase 2 | |
| Completed |
NCT01527422 -
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
|
Phase 1/Phase 2 | |
| Completed |
NCT00834951 -
Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00597714 -
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT00001430 -
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
|
Phase 2 |